B cell engagement with HIV-1 founder virus envelope predicts development of broadly neutralizing antibodies.

Affiliation

Townsley SM(1), Donofrio GC(1), Jian N(1), Leggat DJ(2), Dussupt V(1), Mendez-Rivera L(1), Eller LA(1), Cofer L(1), Choe M(3), Ehrenberg PK(4), Geretz A(1), Gift S(1), Grande R(1), Lee A(1), Peterson C(3), Piechowiak MB(1), Slike BM(1), Tran U(1), Joyce MG(3), Georgiev IS(5), Rolland M(1), Thomas R(1), Tovanabutra S(1), Doria-Rose NA(2), Polonis VR(4), Mascola JR(2), McDermott AB(2), Michael NL(6), Robb ML(1), Krebs SJ(7).
Author information:
(1)U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA.
(2)Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892, USA.
(3)Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA; Emerging Infectious Diseases Branch, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
(4)U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
(5)Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, TN 37212, USA.
(6)Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
(7)U.S. Military HIV Research Program, Center of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA; Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD 20817, USA. Electronic address: [Email]

Abstract

Comment in Cell Host Microbe. 2021 Apr 14;29(4):540-542.